Evommune, Inc. (EVMN) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$28.3M

EPS$-26.36

Market Cap$977.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Luis Pena

CEO & Executive Director

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Founded: 2020
Employees: 48
Headquarters: Palo Alto, California, United States
Website

⚡

Core Efficiency

ROE?

-13.75%

ROA?

-12.57%

D/E Ratio?

0.09

📊

Profitability Ratios

Current Ratio?

8.57

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 2, 2026 (in 115 days)

Annual Report (10-K) — Estimated

Aug 2, 2026

Predicted10-K

Mar 5, 2026

10-KQ4 20252d after period end

Dec 11, 2025

10-QQ3 20251d after period end

Loading company sections...

Evommune, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness